doi:10.16150/j.1671-2870.2020.04.002

Abstract

CLC Number:

R736.1

References 28

[1]	Burman KD, Wartofsky L. Clinical practice. Thyroid no-dules[J]. N Engl J Med, 2015, 373(24):2347-2356. doi: 10.1056/NEJMcp1415786 URL
[2]	Haugen BR, Alexander EK, Bible KC, et al. 2015 Ame-rican Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J]. Thyroid, 2016, 26(1):1-133. doi: 10.1089/thy.2015.0020 pmid: 26462967
[3]	Hegedüs L. Clinical practice. The thyroid nodule[J]. N Engl J Med, 2004, 351(17):1764-1771. doi: 10.1056/NEJMcp031436 URL
[4]	Mandel SJ. A 64-year-old woman with a thyroid nodule[J]. JAMA, 2004, 292(21):2632-2642. pmid: 15572721
[5]	Gharib H, Goellner JR. Fine-needle aspiration biopsy of the thyroid: an appraisal[J]. Ann Intern Med, 1993, 118(4):282-289. pmid: 8420446
[6]	Bongiovanni M, Spitale A, Faquin WC, et al. The Bethesda System for Reporting Thyroid Cytopathology: a meta-analysis[J]. Acta Cytol, 2012, 56(4):333-339. doi: 10.1159/000339959 pmid: 22846422
[7]	Xing M. Molecular pathogenesis and mechanisms of thyroid cancer[J]. Nat Rev Cancer, 2013, 13(3):184-199. doi: 10.1038/nrc3431 URL
[8]	Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma[J]. J Natl Cancer Inst, 2003, 95(8):625-627. doi: 10.1093/jnci/95.8.625 URL
[9]	Yoo SK, Lee S, Kim SJ, et al. Comprehensive analysis of the transcriptional and mutational landscape of follicular and papillary thyroid cancers[J]. PLoS Genet, 2016, 12(8):e1006239. doi: 10.1371/journal.pgen.1006239 URL
[10]	Yoo SK, Song YS, Lee EK, et al. Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer[J]. Nat Commun, 2019, 10(1):2764. doi: 10.1038/s41467-019-10680-5 URL
[11]	Calebiro D, Grassi ES, Eszlinger M, et al. Recurrent EZH1 mutations are a second hit in autonomous thyroid adenomas[J]. J Clin Invest, 2016, 126(9):3383-3388. doi: 10.1172/JCI84894 pmid: 27500488
[12]	Ye L, Zhou X, Huang F, et al. The genetic landscape of benign thyroid nodules revealed by whole exome and transcriptome sequencing[J]. Nat Commun, 2017, 8:15533. doi: 10.1038/ncomms15533 URL
[13]	Goldner WS, Angell TE, McAdoo SL, et al. Molecular variants and their risks for malignancy in cytologically indeterminate thyroid nodules[J]. Thyroid, 2019, 29(11):1594-1605. doi: 10.1089/thy.2019.0278 URL
[14]	Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer[J]. JAMA, 2013, 309(14):1493-1501. doi: 10.1001/jama.2013.3190 URL
[15]	Xing M, Liu R, Liu X, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence[J]. J Clin Oncol, 2014, 32(25):2718-2726. doi: 10.1200/JCO.2014.55.5094 URL
[16]	Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples[J]. J Clin Endocrinol Metab, 2011, 96(11):3390-3397. doi: 10.1210/jc.2011-1469 pmid: 21880806
[17]	Nikiforova MN, Wald AI, Roy S, et al. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer[J]. J Clin Endocrinol Metab, 2013, 98(11):E1852-E1860.
[18]	Nikiforov YE, Carty SE, Chiosea SI, et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay[J]. Cancer, 2014, 120(23):3627-3634. doi: 10.1002/cncr.29038 pmid: 25209362
[19]	Nikiforov YE, Carty SE, Chiosea SI, et al. Impact of the multi-gene ThyroSeq next-generation sequencing assay on cancer diagnosis in thyroid nodules with atypia of undetermined significance/follicular lesion of undetermined significance cytology[J]. Thyroid, 2015, 25(11):1217-1223. doi: 10.1089/thy.2015.0305 pmid: 26356635
[20]	Nikiforova MN, Mercurio S, Wald AI, et al. Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules[J]. Cancer, 2018, 124(8):1682-1690. doi: 10.1002/cncr.31245 pmid: 29345728
[21]	Steward DL, Carty SE, Sippel RS, et al. Performance of a multigene genomic classifier in thyroid nodules with indeterminate cytology: a prospective blinded multicenter study[J]. JAMA Oncol, 2019, 5(2):204-212. doi: 10.1001/jamaoncol.2018.4616 pmid: 30419129
[22]	Chen T, Gilfix BM, Rivera J, et al. The role of the ThyroSeq v3 molecular test in the surgical management of thyroid nodules in the canadian public health care setting[J/OL]. Thyroid, 2020-05-05[2020-05-11]. https://pubmed.ncbi.nlm.nih.gov/32242511/.
[23]	Chudova D, Wilde JI, Wang ET, et al. Molecular classification of thyroid nodules using high-dimensionality genomic data[J]. J Clin Endocrinol Metab, 2010, 95(12):5296-5304. doi: 10.1210/jc.2010-1087 pmid: 20826580
[24]	Alexander EK, Kennedy GC, Baloch ZW, et al. Preope-rative diagnosis of benign thyroid nodules with indeterminate cytology[J]. N Engl J Med, 2012, 367(8):705-715. doi: 10.1056/NEJMoa1203208 URL
[25]	Patel KN, Angell TE, Babiarz J, et al. Performance of a genomic sequencing classifier for the preoperative diagnosis of cytologically indeterminate thyroid nodules[J]. JAMA Surg, 2018, 153(9):817-824. doi: 10.1001/jamasurg.2018.1153 URL
[26]	Livhits MJ, Kuo EJ, Leung AM, et al. Gene expression classifier vs targeted next-generation sequencing in the management of indeterminate thyroid nodules[J]. J Clin Endocrinol Metab, 2018, 103(6):2261-2268. doi: 10.1210/jc.2017-02754 pmid: 29590358
[27]	Nikiforova MN, Tseng GC, Steward D, et al. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility[J]. J Clin Endocrinol Metab, 2008, 93(5):1600-1608. doi: 10.1210/jc.2007-2696 URL
[28]	Mazeh H, Deutch T, Karas A, et al. Next-generation sequencing identifies a highly accurate miRNA panel that distinguishes well-differentiated thyroid cancer from benign thyroid nodules[J]. Cancer Epidemiol Biomarkers Prev, 2018, 27(8):858-863. doi: 10.1158/1055-9965.EPI-18-0055 URL

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 28

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	XU Chenying, LI Yanran, NI Xiaofeng, XU Shangyan, LIN Qing. Efficacy of ultrasonic examination in predicting cervical lymph node metastasis in elderly patients with papillary thyroid carcinoma and analysis of related ultrasound signs [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(03): 343-348.
[2]	ZHAO Ran, ZHAN Weiwei, HOU Yiqing. The application value of computer-aided ultrasound diagnosis system in differentiating malignant from benign thyroid nodules in diffuse thyroid lesions [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(03): 390-394.
[3]	. [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(02): 216-220.
[4]	YANG Yixian, NI Zhongxin, XIA Shujun, ZHOU Wei, ZHAN Weiwei. A comparison of clinicopathologic and ultrasonic features between unifocal and multifocal papillary thyroid carcinoma [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(02): 168-172.
[5]	WANG Xing, WANG Ronghui, ZHANG Guiping, DONG Yijie, ZHOU Wei, ZHAN Weiwei. Diagnostic accuracy of ultrasound-guided fine needle aspiration biopsy for different thyroid carcinoma in 10 388 thyroid nodules: a ten-year study [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(04): 359-363.
[6]	. [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(04): 339-343.
[7]	. [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(04): 344-349.
[8]	GUO Yan, GE Juanjuan, CHEN Chen, YIN Jiming, WANG Xiaolong, CHEN Jiageng, DU Yanwei, DUAN Yuanyuan, FAN Xuelin, ZHENG Lei, WANG Xiyong, ZHAN Weiwei, ZHANG Lu. Diagnostic value of fine needle aspiration biopsy combining with RJ-TIRADS in distinguishing benign and malignant thyroid nodules in elderly patients [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(03): 286-291.
[9]	. [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(02): 188-190.
[10]	. [J]. Journal of Diagnostics Concepts & Practice, 2019, 18(06): 683-684.
[11]	GU Yaoyao, NI Xuejun. Clinical value of ultrasonography in diagnosis of cervical lymph node metastasis of thyroid cancer [J]. Journal of Diagnostics Concepts & Practice, 2019, 18(06): 662-667.
[12]	YU Xiaoqing, ZHAN Weiwei, ZHOU Wei, WU Yu, WANG Yi, LI Weiwei, TAO Lingling, FAN Jinfang. Analysis of lymph node density related clinical and gray-scale sonographic characteristics of papillary thyroid carcinoma [J]. Journal of Diagnostics Concepts & Practice, 2019, 18(05): 555-559.
[13]	YANG Zhifang, FANG Guoping, ZHAN Weiwei, JI Ri. Dedifferentiated solid variant papillary thyroid carcinoma with extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue: a case report with pathological characteristics and literature analysis [J]. Journal of Diagnostics Concepts & Practice, 2019, 18(05): 548-554.
[14]	KUANG Lijun, WANG Yi, LU Caifeng, FAN Jinfang, WU Min, ZHOU Wei. Ultrasounographic finding of thyroid nodule with squamous metaplasia: report of a case and review of literature [J]. Journal of Diagnostics Concepts & Practice, 2019, 18(04): 423-427.
[15]	YANG Chihui, ZHANG Jing, MENG Leijun, GONG Liping, CHANG Qing, ZHANG Hong, ZENG Naiyan. Screening and identification of clinical molecular targets in papillary thyroid cancers [J]. Journal of Diagnostics Concepts & Practice, 2019, 18(04): 402-411.